Leap Therapeutics (LPTX) said Wednesday that updated findings from its phase 2 trial indicate that sirexatamab combined with bevacizumab and chemotherapy improves progression-free survival and overall response rate in patients with advanced colorectal cancer.
Leap reported that patients with elevated DKK1 protein levels who were treated with sirexatamab in addition to bevacizumab and chemotherapy had a 32% higher overall response rate and lived 3.5 months longer without their cancer worsening compared with patients receiving only bevacizumab and chemotherapy.
The company also said that patients who had not previously received anti-VEGF therapy saw a 22% higher ORR and lived 2.6 months longer without disease progression, though overall survival data is still being collected.
The company said the new data supports plans to move sirexatamab into a phase 3 trial, focusing on colorectal cancer patients with elevated DKK1 protein levels or no prior anti-VEGF therapy.
The company's shares were up more than 18% in recent Wednesday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。